Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing
- PMID: 33507480
- PMCID: PMC8406379
- DOI: 10.1007/s10549-020-06079-2
Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing
Abstract
Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating side effect in cancer survivors. This study aimed to assess the characteristics of quantitative sensory testing (QST) and its correlation with patient-reported outcomes (PROs) in cancer patients with and without CIPN.
Methods: We conducted a cross-sectional analysis using baseline data from two clinical trials in solid tumor cancer survivors with no CIPN symptoms rated < 2 on a 0-10 Numerical Rating Scale (NRS) or moderate-to-severe CIPN rated ≥ 4 on the NRS. We collected PROs (NRS, Neuropathic Pain Scale, and Functional Assessment of Cancer Therapy-Gynecologic Oncology Group/Neurotoxicity subscale at baseline. QST [Tactile Threshold (TT), Vibration Threshold (VT), Thermal Threshold (THT)] measurements were used to assess sensory fiber function; they were compared between patients with and without CIPN using Wilcoxon rank-sum tests. We used Spearman correlation coefficients to estimate associations between PROs and QST in all patients.
Results: Among 116 participants with CIPN (median NRS 5.00) and 10 participants without CIPN (median NRS 0.00), the median (interquartile range) TT was 3.84 (3.47, 4.12) and 3.53 (3.00, 3.84) in feet, respectively (p = 0.043). The median VT was 17.90 (9.42, 26.95) and 7.73 (5.94, 11.11) in feet, respectively (p = 0.001). Thermal cool threshold was 30.00 °C (28.90, 30.57) and 30.67 °C (30.57, 30.93), respectively (p = 0.007). Correlation coefficients between PROs and QST measures ranged between 0.02 and 0.50 in absolute magnitude.
Conclusion: Patients with moderate-to-severe CIPN had significantly impaired tactile, vibratory, and thermal thresholds compared to patients without CIPN. QST correlates with PROs, suggesting CIPN symptom severity may correspond to sensory fiber functionality. QST may be incorporated into future CIPN research.
Keywords: Cancer survivors; Chemotherapy; Neuropathy; Patient-reported outcome measures; Quantitative sensory testing.
Figures
Similar articles
-
Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing.Breast Cancer Res Treat. 2019 Dec;178(3):587-595. doi: 10.1007/s10549-019-05416-4. Epub 2019 Aug 27. Breast Cancer Res Treat. 2019. PMID: 31456070 Free PMC article.
-
Mechanistic and thermal characterization of acupuncture for chemotherapy-induced peripheral neuropathy as measured by quantitative sensory testing.Breast Cancer Res Treat. 2023 Feb;197(3):535-545. doi: 10.1007/s10549-022-06846-3. Epub 2022 Dec 17. Breast Cancer Res Treat. 2023. PMID: 36527520 Free PMC article. Clinical Trial.
-
Exploring the reliability and validity of clinically-relevant outcome measures for chemotherapy-induced peripheral neuropathy.Support Care Cancer. 2024 Sep 19;32(10):675. doi: 10.1007/s00520-024-08878-5. Support Care Cancer. 2024. PMID: 39297964
-
Psychophysical and Functional Outcomes in Chemotherapy-induced Peripheral Neuropathy After Spinal Cord Stimulation: A Narrative Review and Case Series.Neuromodulation. 2024 Dec;27(8):1305-1320. doi: 10.1016/j.neurom.2024.06.006. Epub 2024 Jul 31. Neuromodulation. 2024. PMID: 39078349 Free PMC article. Review.
-
Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity.J Peripher Nerv Syst. 2019 Oct;24 Suppl 2:S13-S25. doi: 10.1111/jns.12333. J Peripher Nerv Syst. 2019. PMID: 31647154 Review.
Cited by
-
Foot health and quality of life in women with breast cancer undergoing chemotherapy: a cross-sectional study.J Foot Ankle Res. 2023 Aug 21;16(1):52. doi: 10.1186/s13047-023-00650-y. J Foot Ankle Res. 2023. PMID: 37599367 Free PMC article.
-
Concordance between Self-reported Symptoms and Clinically Ascertained Peripheral Neuropathy among Childhood Cancer Survivors: the St. Jude Lifetime Cohort Study.Cancer Epidemiol Biomarkers Prev. 2021 Dec;30(12):2256-2267. doi: 10.1158/1055-9965.EPI-21-0644. Epub 2021 Sep 28. Cancer Epidemiol Biomarkers Prev. 2021. PMID: 34583966 Free PMC article.
-
BurstDR™ spinal cord stimulation for chemotherapy-induced peripheral neuropathy.Surg Neurol Int. 2025 Jun 6;16:222. doi: 10.25259/SNI_284_2025. eCollection 2025. Surg Neurol Int. 2025. PMID: 40656508 Free PMC article.
-
Changes in Pain Sensitivity in Treatment for Breast Cancer: A 12-Month Follow-Up Case Series.Int J Environ Res Public Health. 2022 Mar 29;19(7):4055. doi: 10.3390/ijerph19074055. Int J Environ Res Public Health. 2022. PMID: 35409738 Free PMC article.
-
Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients' Profiles With Oxaliplatin-Induced Peripheral Neuropathy.Front Pharmacol. 2021 Nov 4;12:744085. doi: 10.3389/fphar.2021.744085. eCollection 2021. Front Pharmacol. 2021. PMID: 34803689 Free PMC article.
References
-
- Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV (2013) Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 31 (21):2699–2707. doi: 10.1200/JCO.2013.49.1514 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous